Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and β-D-N4-hydroxycytidine

Antiviral Chemistry and Chemotherapy

Volumn 15, Issue 1, 2004, Pages 15-22

  Barnard, Dale L ^a   Hubbard, Valerie D ^a   Burton, Jared ^a   Smee, Donald F ^a   Morrey, John D ^a   Otto, Michael J ^b   Sidwell, Robert W ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b PHARMASSET INC   (United States)

Author keywords

Calpain inhibitors; SARSCoV; Severe acute respiratory syndrome associated coronavirus; D N4 hydroxcytidine

Indexed keywords

ANTIVIRUS AGENT; BETA DEXTRO N4 HYDROXYCYTIDINE; CALPAIN INHIBITOR III; CALPAIN INHIBITOR VI; CALPASTATIN; CYTIDINE DERIVATIVE; NEUTRAL RED; NUCLEOSIDE ANALOG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL LINE; CYTOPATHOGENIC EFFECT; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SPECTROPHOTOMETRY; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 2542501662     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020401500102     Document Type: Article

References (31)

1. pro) structure: basis for design of anti-SARS drugs. Science 300:1763-1767.
2. Barnard DL, Sidwell RW, Xiao W, Player MR, Adah S & Torrence PF (1999) 2-5A-antisense inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antiviral Research 41:119-134.
3. Barnard DL, Stowell VD, Seley KL, Hegde VR, Das SR, Rajappan VP, Schneller SW, Smee DF & Sidwell RW (2001) Inhibition of measles virus replication by 5′-nor carbocyclic adenosine analogues. Antiviral Chemistry & Chemotherapy 12:241-250.
4. Barnard DL, Xu ZQ, Stowell VD, Yuan H, Smee, DF, Samy R, Robert W. Sidwell, Nielsen MK, Sun L, Cao H, Li A, Quint C, Deignan J, Crabb J & Flavin MT (2002) Coumarins and pyranocoumarins, potential novel pharmacophores for inhibition of measles virus replication. Antiviral Chemistry & Chemotherapy 13:39-59.
5. Bermejo Martin JF, Jimenez JL & Munoz-Fernandez A (2003) Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. Medical Science Monitor 9:SR29-SR34.
6. Campanacci V, Egloff MP, Longhi S, Ferron F, Rancurel C, Salomoni A, Durousseau C, Tocque F, Bremond N, Dobbe JC, Snijder EJ, Canard B & Cambillau C (2003) Structural genomics of the SARS coronavirus: cloning, expression, crystallization and preliminary crystallographic study of the Nsp9 protein. Acta Crystallographica D Biological Crystallography 59:1628-1631.
7. Cavenaugh PR Jr, Moskwa, PS, Donish WH, Pera PJ, Richardson D, Andrese AP (1990) A semi-automated NR red based chemosensitivity assay for drug screening. Investigational New Drugs 8:347-354.
8. Chou KC, Wei DQ & Zhong WZ (2003) Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochemical & Biophysical Research Communications 308:148-151.
9. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H & Doerr HW (2003a) Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361:2045-2046.
10. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H & Doerr HW (2003b) Treatment of SARS with human interferons. Lancet 362:293-294.
11. Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, Peiris M, Lim W, Stohr K & Osterhaus AD (2003) Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423:240.
12. He ML, Zheng B, Peng Y, Peiris JS, Poon LL, Yuen KY, Lin MC, Kung HF & Guan Y (2003) Inhibition of SARS-associated coronavirus infection and replication by RNA interference. Journal of the American Medical Association 290:2665-2666.
13. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, Wong PC, Li PC, Ho PL, Lam WK, Ng CK, Ip MS, Lai KN, Chan-Yeung M & Tsang KW (2003) High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. American Journal of Respiratory & Critical Care Medicine Aug. 28. [Epub ahead of print as doi:10.1164/rccm, 200306-7660C].
14. Hsueh P-R, Hsiao C-H, Yeh S-H, Wang WK, Chen PJ, Wang JT, Chang SC, Kao CL & Yang PC (2003) Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan. Emerging Infectious Diseases 9:1163-1167.
15. Jia W & Gao W (2003) Is traditional Chinese medicine useful in the treatment of SARS? Phytotherapy Research 17:840-841.
16. Kontoyiannis DP, Pasqualini R & Arap W (2003) Aminopeptidase N inhibitors and SARS. Lancet 361:1558.
17. Koren G, King S, Knowles S & Phillips E (2003) Ribavirin in the treatment of SARS: a new trick for an old drug? Canadian Medical Association Journal 168:1289-1292.
18. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H & Farzan M (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450-454.
19. Meng QH, Dong PL, Guo YB, Zhang K, Liang LC, Hou W & Dong JL (2003) Use of glucocorticoid in treatment of severe acute respiratory syndrome cases. Zhonghua Yu Fang Yi Xue Za Zhi 37:233-235.
20. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y & Yuen KY (2003) HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361:1767-1772.
21. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp, B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ & Bellini WJ (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399.
22. Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LL, Guan Y, Rozanov M, Spaan WJ, Gorbalenya AE (2003) Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. Journal of Molecular Biology 331:991-1004.
23. Stuyver LJ, Whitaker T, McBrayer TR, Hernandez-Santiago BI, Lostia S, Tharnish PM, Ramesh M, Chu CK, Jordan R, Shi J, Rachakonda S, Watanabe KA, Otto MJ & Schinazi RF (2003) Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrobial Agents & Chemotherapy 47:244-254.
24. Thiel V, Ivanov KA, Putics A, Hertzig T, Schelle B, Bayer S, Weissbrich B, Snijder EJ, Rabenau H, Doerr HW, Gorbalenya AE & Ziebuhr J (2003) Mechanisms and enzymes involved in SARS coronavirus genome expression. Journal of General Virology 84:2305-2315.
25. Tisdale M, Ellis M, Klumpp K, Court S, Ford M. (2003) Inhibition of influenza virus transcription by 2′-deoxy-2′-fluoroguanosine. Antimicrobial Agents Chemotherapy 9:2454-2458.
26. von Grotthuss M, Wyrwicz LS & Rychlewski L (2003) mRNA cap-1 methyltransferase in the SARS genome. Cell 113:701-702.
27. Wenzel RP, Edmond MB (2003) Managing SARS amidst uncertainty. New England Journal of Medicine 348:1947-1948.
28. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K & Dimitrov DS (2003) The SARS-CoV S glycoprotein: expression and functional characterization. Biochemical & Biophysical Research Communications 312:1159-1164.
29. Xu X, Liu Y, Weiss S, Arnold E, Sarafianos SG & Ding J (2003) Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Research 31:7117-7130.
30. Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z, Sun L, Mo L, Ye S, Pang H, Gao GF, Anand K, Bartlam M, Hilgenfeld R & Rao Z (2003) The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proceedings of the National Academy of Sciences, USA 100:13190-13195.
31. Zhang R, Guo Z, Lu J, Meng J, Meng J, Zhou C, Zhan X, Huang B, Yu X, Huang M, Pan X, Ling W, Chen X, Wan Z, Zheng H, Yan X, Wang Y, Ran Y, Liu X, Ma J, Wang C & Zhang B (2003) Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA. Chinese Medical Journal (Engl) 116:1262-1264.